Le score PCA3 et l’IRM prostatique permettent-ils de sélectionner les patients candidats a une première série de biopsies prostatiques ?

Thompson, 2006, Assessing prostate cancer risk: results from the Prostate Cancer Prevention Trial, J Natl Cancer Inst, 98, 529, 10.1093/jnci/djj131

Vlaeminck-Guillem, 2008, Value of urinary PCA3 test for prostate cancer diagnosis, Prog Urol, 18, 259, 10.1016/j.purol.2008.03.029

Landers, 2005, Use of multiple biomarkers for a molecular diagnosis of prostate cancer, Int J Cancer, 114, 950, 10.1002/ijc.20760

Deras, 2008, PCA3: a molecular urine assay for predicting prostate biopsy outcome, J Urol, 179, 1587, 10.1016/j.juro.2007.11.038

Kitajima, 2010, Prostate cancer detection with 3T MRI: comparison of diffusion-weighted imaging and dynamic contrast-enhanced MRI in combination with T2-weighted imaging, J Magn Reson Imaging, 31, 625, 10.1002/jmri.22075

Sciarra, 2011, Advances in magnetic resonance imaging: how they are changing the management of prostate cancer, Eur Urol, 59, 962, 10.1016/j.eururo.2011.02.034

Girouin, 2007, Prostate dynamic contrast-enhanced MRI with simple visual diagnostic criteria: is it reasonable?, Eur Radiol, 17, 1498, 10.1007/s00330-006-0478-9

Cheikh, 2009, Evaluation of T2-weighted and dynamic contrast-enhanced MRI in localizing prostate cancer before repeat biopsy, Eur Radiol, 19, 770, 10.1007/s00330-008-1190-8

Hambrock, 2010, Magnetic resonance imaging guided prostate biopsy in men with repeat negative biopsies and increased prostate specific antigen, J Urol, 183, 520, 10.1016/j.juro.2009.10.022

Groskopf, 2006, APTIMA PCA3 molecular urine test: development of a method to aid in the diagnosis of prostate cancer, Clin Chem, 52, 1089, 10.1373/clinchem.2005.063289

Akin, 2006, Transition zone prostate cancers: features, detection, localization, and staging at endorectal MR imaging, Radiology, 239, 784, 10.1148/radiol.2392050949

Dickinson, 2011, Magnetic resonance imaging for the detection, localisation, and characterisation of prostate cancer: recommendations from a European consensus meeting, Eur Urol, 59, 477, 10.1016/j.eururo.2010.12.009

Barentsz, 2012, ESUR prostate MR guidelines 2012, Eur Radiol, 22, 746, 10.1007/s00330-011-2377-y

de la Taille, 2011, Clinical evaluation of the PCA3 assay in guiding initial biopsy decisions, J Urol, 185, 2119, 10.1016/j.juro.2011.01.075

Nam, 2010, Increasing hospital admission rates for urological complications after transrectal ultrasound guided prostate biopsy, J Urol, 183, 963, 10.1016/j.juro.2009.11.043

Marks, 2007, PCA3 molecular urine assay for prostate cancer in men undergoing repeat biopsy, Urology, 69, 532, 10.1016/j.urology.2006.12.014

Haese, 2008, Clinical utility of the PCA3 urine assay in European men scheduled for repeat biopsy, Eur Urol, 54, 1081, 10.1016/j.eururo.2008.06.071

Niaf, 2012, Computer-aided diagnosis of prostate cancer in the peripheral zone using multiparametric MRI, Phys Med Biol, 57, 3833, 10.1088/0031-9155/57/12/3833

Kim, 2010, Diffusion-weighted MRI at 3T for the evaluation of prostate cancer, AJR Am J Roentgenol, 194, 1461, 10.2214/AJR.09.3654

Singh, 2008, Initial clinical experience with real-time transrectal ultrasonography-magnetic resonance imaging fusion-guided prostate biopsy, BJU Int, 101, 841, 10.1111/j.1464-410X.2007.07348.x